Skip to main content

Table 4 Management of patients in the experimental group at day 5

From: Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol

Temperature

CRP

Treatment plan

 < 38 °C

 ≤ 10 mg/L

Corticosteroid taper: oral prednisolone 1 mg/kg/day for 5 days, then 0·5 mg/kg/day for another 5 days, then stop; continue aspirin at 3–5 mg/kg/day for at least 21 days after resolution of fevera

 < 38 °C

 > 10 mg/L

Continue oral prednisolone 2 mg/kg/day until afebrile AND CRP ≤ 10 mg/L (then taper as above) and consider rescue treatment at discretion of local investigator; continue aspirin at 3–5 mg/kg/day for at least 21 days after resolution of fevera

 ≥ 38 °C

 ≤ 10 mg/L

Continue oral prednisolone 2 mg/kg/day until afebrile AND CRP ≤ 10 mg/L (then taper as above) and consider rescue treatment at discretion of local investigator; continue with aspirin at 40 mg/kg/day until afebrile

 ≥ 38 °C

 > 10 mg/L

Continue oral prednisolone 2 mg/kg/day until afebrile AND CRP ≤ 10 mg/L (then taper as above) and consider rescue treatment at discretion of local investigator; continue with aspirin at 40 mg/kg/day until afebrile

  1. aFollowing local standard of care